 Shares of Kronos Bio Inc. KRON, 2.38 jumped 25 in premarket trading on Monday after the company announced a development deal with Roche Holdings ROG, -0.46 Genentech. Kronos has a drug discovery platform that will be used to support Genentechs research in small-molecule drugs for cancer. 